Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

Inclusion Criteria:

1. Subjects must be eligible for and intend to receive LEQEMBI under standard of caretreatment.
2. Male and female subjects ages ≥50 years old.
3. Must be willing to comply with protocol including pupillary dilation to a minimum of 3.5 mm to allow for ocular imaging.
4. Patient or patient's legally authorized representative (LAR) (e.g., spouse or legalguardian) has the ability to understand the purpose and risks of the study and providesigned and dated informed consent and authorization to use protected healthinformation (PHI) in accordance with national and local patient privacy regulations.

Exclusion Criteria:

1. History of acute angle-closure glaucoma or allergic reaction to the protocol-specifiedophthalmic medication for dilation of the pupils.
2. Self-reported or diagnosed history of dense cataracts or other significant mediaopacity that may affect clear images of the retina.
3. Subjects must not have had eye surgery in the past 2 months, be currentlyadministering eye drops relating to previous eye surgery,
4. Unable or unwilling to comply with the protocol requirements.